EyePoint (EYPT) Debt Ratio (2018 - 2023)

EyePoint (EYPT) posted Debt Ratio of 0.22 for Q1 2023, up 1.65% sequentially from 0.22 in Q4 2022, and up 38.54% YoY from 0.16 in Q1 2022.

EyePoint (EYPT) Debt Ratio (2018 - 2023) Analysis & Trends

EyePoint has reported Debt Ratio for 6 years, with the latest figure at 0.22 in Q1 2023.

Quarterly Debt Ratio rose 38.54% year-over-year to 0.22 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was 0.22 (up 38.54% YoY) and the FY2022 annual result came in at 0.22, up 58.9% from the prior year.
Debt Ratio improved to 0.22 in Q1 2023 per EYPT's latest filing, from 0.22 in the prior quarter.
Over five years, Debt Ratio peaked at 0.72 in Q2 2020 and troughed at 0.14 in Q4 2021.
A 5-year average of 0.37 and a median of 0.22 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2019 and 2021: Debt Ratio jumped 200.74% in 2019, then slumped 71.9% in 2021.
Over 5 years, Debt Ratio stood at 0.65 in 2019, then sank by 36.02% to 0.41 in 2020, then slumped by 66.47% to 0.14 in 2021, then surged by 58.9% to 0.22 in 2022, then grew by 1.65% to 0.22 in 2023.
According to Business Quant data, Debt Ratio over the past three periods registered 0.22, 0.22, and 0.18 for Q1 2023, Q4 2022, and Q3 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	EyePoint	1.25 Bn	1.07 Bn	507,000.00	-

Download Data